Rift Valley Fever is a clinically and agriculturally important illness caused by Rift Valley Fever Virus (RVFV), a member of the Bunyaviridae endemic primarily in sub-Saharan Africa. Because of the severe illness it causes in humans and because of recent instances of natural spread outside of Africa, it has been identified as emerging disease agent and/or a potential agent of bioterrorism. The symptoms of RVF in humans can include severe fever, malaise, neurological damage, liver damage, hemorrhagic events, and death. Currently there are no clinically proven treatments for RVFV infection. Development of antiviral strategies requires understanding of the viral replication cycle so that specific steps can be targeted. In the research proposed here, we will characterize an essential molecular interaction in the RVFV replication cycle wherein nucleocapsid protein must recognize and bind to viral RNA sequences. To achieve this goal, we will perform truncation analysis on viral RNA transcripts to determine the minimum requirements for efficient RNA-protein binding. We will also perform a combinatorial in vitro selection scheme (SELEX) to obtain a high affinity RNA aptamer(s) to nucleocapsid protein. Sequence analysis of the aptamers will shed light on nucleocapsid target recognition and will subsequently be used to construct a tool to screen drugs that inhibit the nucleocapsid-RNA interaction. Specifically, the aptamer will be ligated to an RNA module that emits a fluorescent signal when the aptamer is displaced from its nucleocapsid binding site. The drug screening tool will then be used to screen compounds at NSRB. Molecules giving promising results in the aptamer displacement assay will be tested against RVFV replication in cell culture. Owing to its central role in replication, nucleocapsid protein has been recognized as a good potential antiviral target. A novel class of drug targeted against nucleocapsid protein has recently been shown to be effective in inhibiting replication of respiratory syncytial virus, also a negative-sense RNA virus, strongly supporting the potential for developing nucleocapsid as a viable drug target in RVFV (Chapman et al, 2007). This research project fits within the RMRCE Integrated Research Focus on Viral Therapeutics, and will interact directly with PI Brian Gowen (RP 3.2) and the NSRB drug screening core.
Rift Valley fever virus causes significant mortality and morbidity in Africa and the Arabian peninsula and poses a serious threat to other regions of the world due to changing habitats of its insect hosts and because it could be introduced intentionally as a part of a bioterrorism effort. The goal of the research proposed here is to biochemically characterize a specific molecular interaction in the virus replication cycle to exploit it as a drug target. We will screen libraries of small molecules to find drugs that interfere with this essential step.
|Lehman, Stephanie S; Mladinich, Katherine M; Boonyakanog, Angkana et al. (2016) Versatile nourseothricin and streptomycin/spectinomycin resistance gene cassettes and their use in chromosome integration vectors. J Microbiol Methods 129:8-13|
|Knudson, Susan E; Cummings, Jason E; Bommineni, Gopal R et al. (2016) Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis. Tuberculosis (Edinb) 101:8-14|
|Charley, Phillida A; Wilusz, Jeffrey (2016) Standing your ground to exoribonucleases: Function of Flavivirus long non-coding RNAs. Virus Res 212:70-7|
|Phillips, Aaron T; Rico, Amber B; Stauft, Charles B et al. (2016) Entry Sites of Venezuelan and Western Equine Encephalitis Viruses in the Mouse Central Nervous System following Peripheral Infection. J Virol 90:5785-96|
|Westover, Jonna B; Sefing, Eric J; Bailey, Kevin W et al. (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62-8|
|Shankar, Sundaresh; Whitby, Landon R; Casquilho-Gray, Hedi E et al. (2016) Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein. J Virol 90:6799-807|
|York, Joanne; Nunberg, Jack H (2016) Myristoylation of the Arenavirus Envelope Glycoprotein Stable Signal Peptide Is Critical for Membrane Fusion but Dispensable for Virion Morphogenesis. J Virol 90:8341-50|
|Rhodes, Katherine A; Schweizer, Herbert P (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82-90|
|Voge, Natalia V; Perera, Rushika; Mahapatra, Sebabrata et al. (2016) Metabolomics-Based Discovery of Small Molecule Biomarkers in Serum Associated with Dengue Virus Infections and Disease Outcomes. PLoS Negl Trop Dis 10:e0004449|
|Rico, Amber B; Phillips, Aaron T; Schountz, Tony et al. (2016) Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses. Virology 499:30-39|
Showing the most recent 10 out of 244 publications